Evidence map›Paper›PMID 34608281›Full record

ReviewNature reviews. Immunology2022

The interplay of immunology and cachexia in infection and cancer.

Hatoon Baazim, Laura Antonio-Herrera, Andreas Bergthaler

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07237464 (A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Following Single Subcutaneous Injection in Healthy Adult Participants), which is not on this map. Cited by 114 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 1 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07237464 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Following Single Subcutaneous Injection in Healthy Adult Participants

TypeinterventionalSponsorShenzhen Kexing Pharmaceutical Co., Ltd.Ran2025 to 2026Enrolled36ConditionsCancer Cachexia (CC), Cancer Cachexia, Cancer Cachexia SyndromeArmsGB18 injection, Placebo
3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Energy constraint on human health.Trends in endocrinology and metabolism: TEM · 2026
    Review
  5. Article
  6. Review
  7. Low Muscle Density Is Associated with Morbidity and Systemic Inflammation in Colorectal Cancer, Independent of Tumor Factors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Subcutaneous adipose tissue outperforms muscle strength as an indicator of survival and quality of life in patients with cancer: a multicenter cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Evaluation of skeletal muscle indicators following allogeneic hematopoietic stem cell transplantation: verification of skeletal muscle mass adjustment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Hatoon BaazimCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Laura Antonio-HerreraCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-9077-5920
Andreas BergthalerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. abergthaler@cemm.oeaw.ac.at.ORCID http://orcid.org/0000-0003-0597-1976
Austrian Academy of Sciences · ATHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diverse inflammatory diseases, infections and malignancies are associated with wasting syndromes. In many of these conditions, the standards for diagnosis and treatment are lacking due to our limited understanding of the causative molecular mechanisms. Here, we discuss the complex immunological context of cachexia, a systemic catabolic syndrome that depletes both fat and muscle mass with profound consequences for patient prognosis. We highlight the main cytokine and immune cell-driven pathways that have been linked to weight loss and tissue wasting in the context of cancer-associated and infection-associated cachexia. Moreover, we discuss the potential immunometabolic consequences of cachexia on the basis of newly identified pathways and explore the multilayered area of immunometabolic crosstalk both upstream and downstream of tissue catabolism. Collectively, this Review highlights the intricate relationship of the immune system with cachexia in the context of malignant and infectious diseases.

Indexed as

CachexiaNeoplasmsCytokinesHumansMuscle, SkeletalWeight LossCytokines

Identifiers

PMID34608281
PMCPMC8489366
OpenAlexW3202533849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.